Dutch academic drug development setback: NKI experimental medicine rejected

An experimental drug developed by the Netherlands Cancer Institute (NKI) was rejected, marking a setback for academic and non-commercial drug development. The rejection highlights challenges faced by academic institutions in bringing therapies to market, potentially reinforcing the role of commercial pharma. The specific reasons for rejection and next steps remain unclear.